Revance Therapeutics, Inc. (NasdaqGM: RVNC) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc.  Under the terms of the proposed transaction, shareholders of Revance will receive $6.66 in cash for each share of Revance that they own.  Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.